Have a personal or library account? Click to login
The influence of the used applicators on organ and target doses for cervical cancer patients treated with HDR brachytherapy Cover

The influence of the used applicators on organ and target doses for cervical cancer patients treated with HDR brachytherapy

Open Access
|Sep 2022

References

  1. 1. Zhang X, Zeng Q, Cai W, Ruan W. Trends of cervical cancer at global, regional, and national level: data from the Global Burden of Disease study 2019. BMC Public Health. 2021;21(1):894. https://doi.org/10.1186/s12889-021-10907-5
  2. 2. Green J, Kirwan J, Tierney J et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. The Lancet. 2001;358(9284):781-786. https://doi.org/10.1016/s0140-6736(01)05965-7
  3. 3. Vinin N, Jones J, Ajas V et al. Organ at Risk Doses during High Dose Rate Intracavitary Brachytherapy for Cervical Cancer: A Dosimetric Study. International Journal of Medical Physics, Clinical Engineering and Radiation Oncology. 2018;07(04):472-478. https://doi.org/10.4236/ijmpcero.2018.78040
  4. 4. Pötter R, Haie-Meder C, Van Limbergen E et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiotherapy and Oncology. 2006;78(1):67-77. https://doi.org/10.1016/j.radonc.2005.11.014
  5. 5. Nag S, Erickson B, Thomadsen B et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. International Journal of Radiation Oncology*Biology*Physics. 2000;48(1):201-211. https://doi.org/10.1016/s0360-3016(00)00497-1
  6. 6. Swamidas J, Mahantshetty U. ICRU report 89: prescribing, recording, and reporting brachytherapy for cancer of the cervix. Journal of Medical Physics. 2017;42(suppl1);48.
  7. 7. Romano K, Hill C, Trifiletti D et al. High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events. Radiation Oncology. 2018;13(1). https://doi.org/10.1186/s13014-018-1074-2604883830012164
  8. 8. Tornero-López A, Guirado D. Radiobiological considerations in combining doses from external beam radiotherapy and brachytherapy for cervical cancer. Reports of Practical Oncology & Radiotherapy. 2018;23(6):562-573. https://doi.org/10.1016/j.rpor.2018.05.007627727230534020
  9. 9. Wang C, Huang E, Sun L et al. Clinical comparison of two linear-quadratic model-based isoeffect fractionation schemes of high-dose-rate intracavitary brachytherapy for cervical cancer. International Journal of Radiation Oncology*Biology*Physics. 2004;59(1):179-189. https://doi.org/10.1016/j.ijrobp.2003.10.02515093915
  10. 10. Vinin N, Dharmarajan A, Sahin PM et al. Dosimetric comparison of tandem and ovoids with tandem and ring for intracavitary brachytherapy for carcinoma cervix. Oncology and Radiotherapy. 2019;46(1):39-42.
  11. 11. Rangarajan R. Dosimetric evaluation of image based brachytherapy using tandem ovoid and tandem ring applicators. Reports of Practical Oncology & Radiotherapy. 2018;23(1):57-60. https://doi.org/10.1016/j.rpor.2017.12.006576784429348735
  12. 12. Levin D, Menhel J, Rabin T, Pfeffer M, Symon Z. Dosimetric Comparison of Tandem and Ovoids vs. Tandem and Ring for Intracavitary Gynecologic Applications. Medical Dosimetry. 2008;33(4):315-320. https://doi.org/10.1016/j.meddos.2008.06.00318973861
  13. 13. Erickson B, Jones R, Rownd J et al. Is the tandem and ring applicator a suitable alternative to the high dose rate selectron tandem and ovoid applicator? Journal of Brachytherapy International. 2000;16(2):131-144.
  14. 14. Harmon G, Diak A, Shea S, Yacoub J, Small W, Harkenrider M. Point A vs. HR-CTV D90 in MRI-based cervical brachytherapy of small and large lesions. Brachytherapy. 2016;15(6):825-831. https://doi.org/10.1016/j.brachy.2016.08.010
  15. 15. Dumane V, Yuan Y, Sheu R, Gupta V. Computed tomography-based treatment planning for high-dose-rate brachytherapy using the tandem and ring applicator: influence of applicator choice on organ dose and inter-fraction adaptive planning. J Contemp Brachytherapy. 2017;3:279-286. https://doi.org/10.5114/jcb.2017.68519
  16. 16. Noyes W, Peters N, Thomadsen B et al. Impact of “optimized” treatment planning for tandem and ring, and tandem and ovoids, using high dose rate brachytherapy for cervical cancer. International Journal of Radiation Oncology*Biology*Physics. 1995;31(1):79-86. https://doi.org/10.1016/0360-3016(94)00401-6
  17. 17. Siavashpour Z, Aghamiri M, Jaberi R et al. A comparison of organs at risk doses in GYN intracavitary brachytherapy for different tandem lengths and bladder volumes. J Appl Clin Med Phys. 2016;17(3):5-13. https://doi.org/10.1120/jacmp.v17i3.5584569092727167253
  18. 18. Suryadevara A, Kumar M, Vasundhara E, Alluri K, Ahamed S, Guduru S. A dosimetric comparison between applicators used for brachytherapy in carcinoma cervix – A single-institute prospective study. Indian J Cancer. 2018;55(3):230. https://doi.org/10.4103/ijc.ijc_659_17
DOI: https://doi.org/10.2478/pjmpe-2022-0017 | Journal eISSN: 1898-0309 | Journal ISSN: 1425-4689
Language: English
Page range: 139 - 149
Submitted on: Mar 30, 2022
Accepted on: Aug 8, 2022
Published on: Sep 30, 2022
Published by: Polish Society of Medical Physics
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2022 Beata Pszczółkowska, Michał Bijok, Beata Brzozowska, published by Polish Society of Medical Physics
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.